

By: Burrows

H.B. No. 1313

A BILL TO BE ENTITLED

1 AN ACT
2 relating to a study on the side effects, adverse reactions,
3 including death, and the effectiveness of vaccines against the
4 SARS-CoV-2 virus (COVID-19) or its variants.

5 BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS:

6 SECTION 1. (a) In this section:

7 (1) "Commission" means the Health and Human Services
8 Commission.

9 (2) "Executive commissioner" means the executive
10 commissioner of the Health and Human Services Commission.

11 (3) "Department" means the Department of State Health
12 Services.

13 (4) "COVID 19" means the SARS-CoV-2 virus and any of
14 its variants.

15 (5) "Vaccine" means a substance used to stimulate
16 immunity to a particular infectious disease or pathogen, typically
17 prepared from an inactivated or weakened form of the causative
18 agent or from its constituents or products.

19 (b) The Commission in collaboration with the Department
20 shall conduct a study to assess the full and complete adverse
21 reactions, including death, and effectiveness of each type of
22 vaccine used in Texas to defend the human body against "COVID 19.
23 The Report must include:

24 (1) The immediate short-term side effects and adverse

1 reactions recipients experienced from taking the various Covid-19
2 vaccines used in Texas; including but not limited to include:

- 3 i. Pain, swelling, or redness where the shot was
4 given
- 5 ii. Mild fever
- 6 iii. Chills
- 7 iv. Feeling tired
- 8 v. Headache
- 9 vi. Muscle and joint aches

10 (2) The immediate serious side effects and adverse
11 reactions recipients experienced from taking the various Covid-19
12 vaccines used in Texas; including but not limited to include:

- 13 i. difficulty breathing;
- 14 ii. swelling of the face and throat;
- 15 iii. accelerated heartbeat;
- 16 iv. a body rash;
- 17 v. dizziness; and
- 18 vi. weakness

19 (3) Any long-term side effects and adverse reactions
20 recipients have experienced from taking the various Covid-19
21 vaccines used in Texas; including but not limited to include:

- 22 i. paralysis;
- 23 ii. Myocarditis;
- 24 iii. clotting disorders;
- 25 iv. Thrombosis with Thrombocytopenia Syndrome
26 (TTS);
- 27 v. Guillain-Barré syndrome (GBS);

- 1 vi. difficulty thinking or "brain fog,"
- 2 vii. chronic pain;
- 3 viii. tiredness and fatigue;
- 4 ix. loss of taste;
- 5 x. depression;
- 6 xi. anxiety; and
- 7 xii. death.

8 (4) Any misrepresentations about the effectiveness or
9 dangers of taking of the vaccine by its manufacturers or any
10 governmental agency; and,

11 (5) Any concealment of information about the
12 effectiveness or dangers of taking of the vaccine by its
13 manufacturers or any governmental agency.

14 (c) The Commission and the Department shall gather
15 information for the report from:

16 (1) information collected by the Commission and the
17 Department, including information from the department's vital
18 statistics unit and the state Medicaid program; and

19 (2) hospitals, treatment centers, available surveys,

20 (3) and other relevant sources.

21 SECTION 2. (a) Not later than January 1, 2024, the
22 Commission and Department shall prepare and submit to the Governor,
23 Lieutenant Governor, the Speaker of the House of Representatives,
24 and the Chairpersons of the relevant Texas legislative committees
25 with jurisdiction over the Commission and the Department, a copy of
26 the report, summary of any findings, and any recommendations for
27 legislative or executive action to reduce the prevalence of

1 COVID-19 Vaccine side effects. The department may post the report
2 on the department's Internet website.

3 (b) The Commission and Department may accept gifts, grants,
4 and donations from any source to fund expenses incurred by the
5 Commission and the Department in preparing the report.

6 SECTION 3. This Act expires September 1, 2025.

7 SECTION 4. This Act takes effect immediately if it receives
8 a vote of two-thirds of all the members elected to each house, as
9 provided by Section 39, Article III, Texas Constitution. If this
10 Act does not receive the vote necessary for immediate effect, this
11 Act takes effect September 1, 2023.